Stress-activated MAP kinases in cardiac remodeling and heart failure: New insights from transgenic studies

Trends in Cardiovascular Medicine

Volumn 14, Issue 2, 2004, Pages 50-55

  Petrich, Brian G ^a   Wang, Yibin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSGENICS;

EID: 1542613386     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2003.11.002     Document Type: Review

References (51)

1. Adams J., Sakata Y., Davis M.G.et al. Enhanced galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA. 95:1998;10,140-10,145.
2. Adams R.H., Porras A., Alonso G.et al. Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell. 6:2000;109-116.
3. American Heart Association: 2002. 2002 heart and stroke statistical update. Dallas, Texas, American Heart Association, 2001.
4. Aoki H., Kang P.M., Hampe J.et al. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem. 277:2002;10,244-10,250.
5. Barger P.M., Browning A.C., Garner A.N.et al. P38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor alpha: a potential role in the cardiac metabolic stress response. J Biol Chem. 276:2001;44,495-44,501.
6. Barker R.J., Gourdie R.G. JNK bond regulation: why do mammalian hearts invest in connexin43? Circ Res. 91:2002;556-558.
7. Barr R.K., Bogoyevitch M.A. The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). Int J Biochem Cell Biol. 33:2001;1047-1063.
8. Behr T.M., Nerurkar S.S., Nelson A.H.et al. Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation. 104:2001;1292-1298.
9. Braz J.C., Bueno O.F., Liang Q.et al. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest. 111:2003;1475-1486.
10. Bueno O.F., Molkentin J.D. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res. 91:2002;776-781.
11. Bueno O.F., De Windt L.J., Tymitz K.M.et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19:2000;6341-6350.
12. Bulavin D.V., Saito S., Hollander M.C.et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 18:1999;6845-6854.
13. Choukroun G., Hajjar R., Kyriakis J.M.et al. Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. J Clin Invest. 102:1998;1311-1320.
14. Choukroun G., Hajjar R., Fry S.et al. Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. J Clin Invest. 104:1999;391-398.
15. Communal C., Colucci W.S., Remondino A.et al. Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium. J Card Fail. 8:2002;86-92.
16. Cook S.A., Sugden P.H., Clerk A. Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. J Mol Cell Cardiol. 31:1999;1429-1434.
17. Degousee N., Martindale J., Stefanski E.et al. Map kinase kinase 6-p38 map kinase signaling cascade regulates cyclooxygenase-2 expression in cardiac myocytes in vitro and in vivo. Circ Res. 92:2003;757-764.
18. Dougherty C.J., Kubasiak L.A., Prentice H.et al. Activation of c-Jun N-terminal kinase promotes survival of cardiac myocytes after oxidative stress. Biochem J. 362:2002;561-571.
19. Gutstein D.E., Morley G.E., Tamaddon H.et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res. 88:2001;333-339.
20. Hirosumi J., Tuncman G., Chang L.et al. A central role for JNK in obesity and insulin resistance. Nature. 420:2002;333-336.
21. Hoover H.E., Thuerauf D.J., Martindale J.J.et al. Alpha b-crystallin gene induction and phosphorylation by MKK6-activated p38. A potential role for alpha b-crystallin as a target of the p38 branch of the cardiac stress response. J Biol Chem. 275:2000;23,825-23,833.
22. Hreniuk D., Garay M., Gaarde W.et al. Inhibition of c-Jun N-terminal kinase 1, but not c-Jun N-terminal kinase 2, suppresses apoptosis induced by ischemia/reoxygenation in rat cardiac myocytes. Mol Pharmacol. 59:2001;867-874.
23. Huang C., Ma W.Y., Maxiner A.et al. P38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J Biol Chem. 274:1999;12,229-12, 235.
24. Ichijo H., Nishida E., Irie K.et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science. 275:1997;90-94.
25. Izumiya Y., Kim S., Izumi Y.et al. Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling. Circ Res. 93:2003;874-883.
26. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:2002;1911-1912.
27. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 81:2001;807-869.
28. Lemke L.E., Bloem L.J., Fouts R.et al. Decreased p38 MAPK activity in end-stage failing human myocardium: P38 MAPK alpha is the predominant isoform expressed in human heart. J Mol Cell Cardiol. 33:2001;1527-1540.
29. Liang Q., Bueno O.F., Wilkins B.J.et al. C-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. EMBO J. 22:2003;5079-5089.
30. Liao P., Georgakopoulos D., Kovacs A.et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci USA. 98:2001;12,283-12,288.
31. Liao P., Wang S.Q., Wang S.et al. P38 mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circ Res. 90:2002;190-196.
32. Ma X.L., Kumar S., Gao F.et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation. 99:1999;1685-1691.
33. McDonald P.H., Chow C.W., Miller W.E.et al. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science. 290:2000;1574-1577.
34. Minamino T., Yujiri T., Terada N.et al. MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq. Proc Natl Acad Sci USA. 99:2002;3866-3871.
35. Molkentin J.D., Dorn I.G. 2nd Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol. 63:2001;391-426.
36. Olson E.N., Schneider M.D. Sizing up the heart: development redux in disease. Genes Dev. 17:2003;1937-1956.
37. Ono K., Han J. The p38 signal transduction pathway: activation and function. Cell Signal. 12:2000;1-13.
38. Petrich B.G., Gong X., Lerner D.L.et al. C-Jun N-terminal kinase activation mediates downregulation of connexin43 in cardiomyocytes. Circ Res. 91:2002;640-647.
39. Petrich B.G., Liao P., Wang Y. Using a gene-switch transgenic approach to dissect distinct roles of MAP kinases in heart failure. Cold Spring Harb Symp Quant Biol. 67:2002;429-437.
40. Petrich B.G., Molkentin J.D., Wang Y. Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxp-mediated DNA recombination. FASEB J. 17:2003;749-751.
41. Rebsamen M.C., Capoccia R., Vallotton M.B.et al. Role of cyclooxygenase 2, p38 and p42/44 MAPK in the secretion of prostacyclin induced by epidermal growth factor, endothelin-1 and angiotensin II in rat ventricular cardiomyocytes. J Mol Cell Cardiol. 35:2003;81-89.
42. Sadoshima J., Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol. 59:1997;551-571.
43. Sadoshima J., Montagne O., Wang Q.et al. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J Clin Invest. 110:2002;271-279.
44. Sugden P.H. Signalling pathways in cardiac myocyte hypertrophy. Ann Med. 33:2001;611-622.
45. Takeda K., Matsuzawa A., Nishitoh H.et al. Roles of MAPKKK ASK1 in stress-induced cell death. Cell Struct Funct. 28:2003;23-29.
46. Tamura K., Sudo T., Senftleben U.et al. Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell. 102:2000;221-231.
47. Wang Y., Huang S., Sah V.P.et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem. 273:1998;2161-2168.
48. Wang Y., Su B., Sah V.P.et al. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem. 273:1998;5423-5426.
49. Zechner D., Thuerauf D.J., Hanford D.S.et al. A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J Cell Biol. 139:1997;115-127.
50. Zhang S., Ren J., Zhang C.E.et al. Role of 14-3-3-mediated p38 mitogen-activated protein kinase inhibition in cardiac myocyte survival. Circ Res. 93(11):2003;1026-1028. Nov 28.
51. Zhang S., Weinheimer C., Courtois M.et al. The role of the grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest. 111:2003;833-841.